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Abstract: Site-selective chemical modifications that target 
proteinogenic amino acid residues complement the methods entailing 
genetic manipulation, thereby allowing straightforward and rapid 
access to engineered proteins. The incorporation of the trifluoromethyl 
group into amino acids within a peptide sequence results in relevant 
peptidomimetics with unique biomedicinal properties. As a result, the 
last decade has witnessed the development of a powerful set of 
protocols toward the selective trifluoromethylation of small-to-medium 
size peptides and proteins in a late-stage fashion. This minireview 
seeks to highlight those particularly compelling cases published in the 
last years. 
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1. Introduction
Despite their low abundance in naturally occurring molecules, 
organofluorine compounds have been found widespread 
applications in pharmaceutical chemistry, agrochemistry, 
biomedicine and material science.[1] The installation of a fluorine-
containing motif into a given molecule typically ushers in a drastic 
change of its physicochemical properties such as solubility and 
lipophilicity. As a result, fluorinated compounds commonly exhibit 
improved metabolic stability, increased bioavailability and cellular 
membrane permeability.[1] In particular, the trifluoromethyl group 
stands out among the most privileged moieties of the fluoroalkyl 
series and a sheer number of drugs and agrochemicals on the 
worldwide market incorporate such a unique scaffold. The 
assembly of trifluoromethylated compounds has traditionally 
entailed the usage of trifluoromethylated synthons upon multi-
step and long synthetic sequences. However, with the advent of 
metal catalysis, the latter have been replaced by more practical 
transition metal-catalyzed trifluoromethylations of organic halides 
or organometallic reagents, thus allowing the convenient 
introduction of the trifluoromethyl group in a modular and late-
stage fashion.[2] While conceptually innovative, the use of pre-
functionalized compounds represents a serious drawback, which 
often diminishes the practicality of the methods. In this regard, the 
last decade has witnessed the outpour of challenging direct 
trifluoromethylation reactions of otherwise unreactive C–H 
bonds,[3] thereby spawning a more straightforward and 
sustainable platform to forge trifluoromethylated compounds.  
A variety of trifluoromethylating agents can be utilized in these 
endeavors, such as electrophilic Umemoto[4] and Togni 
reagents,[5] nucleophilic Ruppert-Prakash reagent[6] or Langlois 
reagent,[7] among others (Figure 1). Whereas Langlois reagent is 
essentially selected to perform radical trifluoromethylation 
reactions, electrophilic radical trifluoromethyl species can be also 
generated from Umemoto and Ruppert-Prakash reagents upon 
reaction with an oxidant or a copper catalyst, respectively, as well 
as from trifluoromethylsulfonyl chloride (CF3SO2Cl) through 
photoredox catalysis.[8] Despite their common use in academic 
laboratories, the high price or multi-step synthesis which some of 
them required have limited the application of some of these CF3 
sources in industrial environments. Accordingly, the development 
of cost-efficient new trifluoromethyl sources represents a 
challenging task of capital importance to improve the performance 
and practicality of existing trifluoromethylation techniques in the 
context of downstream functionalizations of relevant biomolecules. 




Figure 1. Common trifluoromethylating agents. 
The site-selective chemical modification of biomolecules remains 
an unmet challenge of paramount importance within chemical 
biology, drug discovery and other disciplines.[9] In this respect, 
peptides rank among the most important classes of biomolecules 
due to their wide variety of essential roles in living organisms.[10a,b] 
Owing to the often improved biological activities and 
pharmacokinetics of the resulting engineered biomolecules, there 
is a long-standing interest in the manipulation of oligopeptides and 
proteins in a tailored manner.[10] In the last years, the development 
of innovative techniques for the straightforward diversification of 
amino acid residues in peptide settings has become a prime goal 
of utmost importance in the burgeoning area of bioconjugation 
and proteomics.[11] Indeed, the landscape of peptide chemistry is 
currently experiencing an exponential growth, thereby 
dramatically expanding the available chemical toolbox and 
streamlining the rapid assembly of non-proteinogenic α-amino 
acids and peptides derived thereof.[12] Despite formidable 
advances in the field, chemoselective diversification of peptides 
still remains a daunting challenge. With the aim to complement 
recent reviews on the topic,[12,13] herein we will focus on the latest 
advances in site-selective late-stage trifluoromethylations of 
oligopeptides and proteins. The main achievements in the field 
have been categorized according to the nature of the amino acid 
residue that undergoes the corresponding fluorination reaction. 
The objective of this user guide is to offer a rationale assessment 
of both the advantages and limitations derived from the existing 
methodologies up to early 2020. Crucial elements of each 
reactions, including compatibility with other canonical amino acid 
residues as well as detailed aspects of the underlying mechanism, 
when applicable, will be commented. The construction of 
trifluoromethylated peptides based on the use of fluorinated 
precursors are beyond the scope of this mini-review[14] and only 
trifluoromethylation protocols occurring within existing peptides or 
proteins in a late-stage manner will be discussed herein. 
2. Trifluoromethylation of Peptides 
The incorporation of the trifluoromethyl group into amino acids 
within a peptide sequence results in relevant peptidomimetics 
with unique biomedicinal and pharmaceutical properties.[15] Driven 
by those outstanding applications, an upsurge of site-selective 
trifluoromethylations have been lately described to perform the 
chemoselective modification of peptides and proteins bearing 
cysteine (Cys), tyrosine (Tyr), histidine (His) and tryptophan (Trp) 
residues. In the following section, the methods available until early 
2020 will be comprehensively analyzed. 
2.1. Trifluoromethylation of Cysteine (Cys) 
Due to the chemical versatility of its thiol-containing polar, 
ionizable side chain, Cys occupies a distinguished place in the 
realm of bioconjugation.[12i] In particular, the substantial 
nucleophilic character of the thiol motif renders Cys unit an ideal 
platform for targeted functionalization.[16] Early examples on the 
S-trifluoromethylation of a Cys residue are traced back to 90s, 
when Soloshonok[17] and Langlois[18] independently utilized CF3I 
in liquid ammonia under ultraviolet irradiation and CF3SO2Na in 
combination with tert-butyl hydroperoxide (TBHP), respectively, 
for the assembly of simple trifluoromethylated Cys amino acids. 
Innovation aside, the latter suffered from serious downsides in 
terms of operational practicality, and they were only applied to a 
limited number of simple systems. Later on, Togni and co-workers 
reported on the synthesis and application of a new family of 
electrophilic hypervalent iodine reagents for the efficient 
trifluoromethylation of a vast array of nucleophilic compounds, 
including simple Cys units.[19] Prompted by the excellent 
performance of the so-called “Togni reagents”, Togni and 
Seebach groups unlocked their full synthetic potential and 
reported jointly on their use for the S-trifluoromethylation of more 
complex α- and β-Cys-containing peptides (of up to 13-residues 
long).[20a] The exquisite selectivity toward soft nucleophiles (with a 
high lying highest occupied molecular orbital, HOMO) over hard 
nucleophiles such as amines or alcohols was harnessed to carry 
out the process in an aqueous solution of MeOH at cryogenic 
temperatures (Scheme 1). Remarkably, a high number of amino 
acid residues such as lysine (Lys), aspartic acid (Asp) or 
threonine (Thr), among others, were perfectly accommodated and 
remained intact along the trifluoromethylation reaction. Likewise, 
the process was applied to unprotected native peptides bearing 
both free-amino and carboxyl groups at terminal positions of the 
peptide sequence. Notably, the trifluoromethylation of the cyclic 
disulfide derivative octreotide[20b] (commercialized by Novartis as 
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Sandostatin®) of high structural complexity resulted in separable 
mixtures of ring-opened octapeptides bearing the S-
trifluoromethylated Cys residues together with the cyclopeptidic 
octreotide with the trifluoromethylated Trp unit. They further 
demonstrated that the embedded CF3 motif could be reduced 
under Birch reaction conditions, thereby resulting in an overall 
rapid and efficient Cys/Ala conversion.[20a] The great versatility of 
hypervalent iodine reagents within the field of bioconjugation was 
next demonstrated by the selective installation of other 
perfluoroalkyl groups into simple Cys residues[20c] and Cys-
containing complex proteins,[20d]  even in the presence of a highly 
nucleophilic Lys residue.  
 
Scheme 1. S-Triluoromethylation of Cys derivatives with Togni reagents. 
Building on their successful trifluoromethylation of aromatic thiols 
upon visible-light induced photocalysis,[21] Noël group developed 
a convenient technique for the S-trifluoromethylation and 
perfluoroalkylation of Cys residues with CF3I and other 
perfluoroalkyl iodide derivatives, respectively.[22] While the 
process could occur to some extent in the absence of any 
photocatalyst, the use of Ru(bpy)3Cl2 resulted in more efficient, 
cleaner and faster reactions (Scheme 2). Furthermore, the 
performance of the process in continuous flow notably enhanced 
the reaction rates, thereby providing higher yields in a shorter 
reaction time (5 min in flow vs 2h in batch). In this respect, the use 
of micro-reactors enabled a scalable, yet safe, handle of the 
customarily tedious gaseous CF3I. The use of a variety of 
perfluoroalkyl iodides of variable length (C3 to C10) represented a 
salient feature of the method due to the higher hydrophobicity of 
the resulting cysteine derivatives, which may favor their 
participation in protein interactions within a biological environment.  
 
Scheme 2. S-Triluoromethylation of Cys derivatives under photoredox catalysis. 
The visible-light induced S-trifluoromethylation reaction was 
assumed to proceed through the mechanism disclosed in 
Scheme 2. Tris(2,2’-bipyridine)ruthenium catalyst was easily 
excited by an initial blue light absorption and the ensuing 
photoexcited species [Ru(bpy)3]2+* was reductively quenched by 
the organic base TMEDA (sacrificial reducing agent). The so-
formed highly reduced [Ru(bpy)3]+ was further oxidized to its 
ground state upon generation of the transient electrophilic 
trifluoromethyl radical or its perfluoroalkyl analogue through a 
Single Electron Transfer (SET) event. The latter eventually 
reacted with the Cys residue to forge the corresponding S–CF3 
linkage. Based on the obtained quantum yield value, the authors 
proposed that the formation of the targeted neutral 
trifloromethylated Cys product could reasonably occur by reaction 
with the starting fluoroalkyl iodide derivative upon a chain-
propagating SET, hence ruling out an alternative chain-
terminating SET step with the in situ formed TMEDA+.  
The tremendous importance of positron emission tomography 
(PET) as a molecular imaging technique to visualize biochemical 
processes in vivo has certainly fueled ground-breaking 
discoveries in the selective 18F-radiolabeling of peptides and 
proteins.[23] As a result, radiolabeled amino acids stand out as an 
important class of tumor-specific imaging tracers.[24] In 2018 Davis 
and Gouverneur jointly designed the elegant synthesis and 
application of the 18F-labeled Umemoto reagent, which was found 
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highly useful for tagging a vast array of Cys-containing unmodified 
peptides of high structural complexity in a radioactive fashion.[25]  
 
Scheme 3. 18F-Trifluoromethylation of Cys-containing unmodified peptides 
(RCC = radiochemical conversion). 
The radiolabeled reagent was prepared through a halogen 
exchange 18F-fluorination with 18F-fluoride followed by an 
oxidative cyclization with oxone and trifluoromethanesulfonic 
anhydride. Importantly, the 18F-trifluoromethylation process could 
be accomplished at room temperature in a very short reaction 
time (10 to 20 min) in the presence of a base such as 4-
dimethylaminopyridine (DMAP) or KHCO3. Remarkably, the 
method was deemed water-tolerant, which represents an added 
bonus toward its application in protein engineering. The method 
exhibited an excellent chemoselectivity profile, and boded well 
with a wide range of Cys-containing oligopeptides bearing Thr, 
Lys, asparagine (Asn), serine (Ser), arginine (Arg) or glutamic 
acid (Glu), among others (Scheme 3). The presence of amino 
acids with aromatic side chains such as His and Trp spawned the 
target S-trifluoromethylated Cys residues as the major products, 
accompanied with C2-trifluoromethylated products of the 
corresponding imidazole and indole rings, respectively. Of 
paramount importance is the successful 18F-radiolabeling of 
cyclopeptides bearing the biomedicinally relevant Arg-Gly-Asp 
(RGD) sequence as well as glutathione, extensively used 
radioligands in PET studies. Preliminary biodistribution 
experiments evidenced the viability of the resulting 18F-SCF3 
tagged peptides for imaging techniques. In this regard, in vivo 
studies with related 18F-trifluoromethyl Cys residues, prepared 
from serine-derived cyclic sulfamidates through a nucleophilic 
18F-trifluoromethylthiolation followed by a final deprotection 
reaction, have recently shown high potential as efficient tracers 
for glioma imaging.[26] 
2.2. Trifluoromethylation of Tryptophan (Trp) 
Among the natural proteinogenic amino acids, Trp is the least 
abundant one with a frequency of about 1.4%;[27] however, around 
90% of native proteins contain at least one Trp residue along their 
primary sequence.[28] Therefore, targeting Trp units represents a 
promising avenue for bioconjugation of proteins and expanding 
their functional diversity as biochemical tools and therapeutic 
agents.[29] The C2-modification of the indole ring of the Trp residue 
constitutes the most widely explored diversification technique 
within peptide chemistry to this day.[12a] In fact, a number of 
chemical transformations performed in simple indole systems, 
which leveraged its innate chemical reactivity as a highly electron-
rich motif, have been lately translated into elegant Trp-
modification reactions, including the site-selective C2-
trifluoromethylation.[30] The trifluoromethyl radical is a highly 
electrophilic species with a low-lying singly occupied molecular 
orbital (SOMO) prone to react with electron-rich motifs such as 
alkenes or heteroarenes.[8,31] By harnessing the latter reactivity, 
the C2-trifluoromethylation of simple N-protected tryptophan 
compounds have been achieved upon the use of different 
trifluoromethyl sources (Scheme 4). 
 
Scheme 4. Trifluoromethylation of simple Trp derivatives. 
In 2010 Sodeoka and co-workers disclosed an efficient Cu-
catalyzed electrophilic trifluoromethylation featuring Togni 
reagent II as the CF3 source for the modification of a vast array of 
indoles, including the Trp derivative Ac-Trp-OMe.[32] More recently, 
the radical trifluoromethylation of Ac-Trp-OMe has been achieved 
by using Ummemoto reagents as practical sources for the 
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production of the corresponding radical trifluoromethyl species by 
reaction with the electron-donor N-methylmorpholine (NMM)[33] or 
under photo-irradiation conditions.[34] Likewise, the organic 
semiconductor mesoporous graphitic carbon nitride (mpg-CN) 
has proven a sustainable, yet highly efficient photocatalyst for the 
C2-trifluoromethylation of Boc-Trp-OEt with both Langlois 
reagent[35] and CF3SO2Cl.[36] All these pioneering studies in the 
preparation of the C2-trifluoromethylated Trp unit were mostly 
focused on the modification of indoles and related heteroarenes, 
and hence only isolated examples of Trp-based compounds were 
reported. Likewise, in 2017 Li and co-workers reported a redox-
neutral and catalyst-free light-induced innovative protocol to 
generate CF3 radicals for the functionalization of a number of 
(hetero)arenes, including a couple of examples of Trp 
derivatives.[37] After careful evaluation of different trifluoromethyl 
compounds, they identified 1-phenyl-2-
[(trifluoromethyl)sulfonyl]propan-1-one as the most effective 
reagent in these endeavors (Scheme 5). Upon light irradiation, the 
latter was proposed to produce the reactive electrophilic CF3 
species along with a highly stabilized and bulky alkyl radical of 
comparatively lower reactivity toward the corresponding electron-
rich heteroarene. Despite its low-atom economy, the latter non-
gaseous trifluoromethyl source may be a rather convenient 
alternative to handle in pharmaceutical environments. 
 
Scheme 5. Redox-neutral light-induced trifluoromethylation. 
Although not applied toward the installation of the trifluoromethyl 
group, in 2017 Chen and co-workers devised a C2-selective 
photochemical perfluoroalkylation of a few Trp-containing 
peptides (Scheme 6).[38] As highlighted before,[22] the introduction 
of perfluoroalkyl groups into a given molecule is of great 
importance because the latter can alter the physicochemical 
properties of the resulting oligopeptide. The success of the 
method relied on the use of N,N,N’,N’-tetraethylethylenediamine 
(TEEDA), which upon coordination with the starting perfluroalkyl 
iodide through the formation of halogen bond adducts, enabled 
the process to occur under low-intensity irradiation (compact 
fluorescent lamp, UV or even sunlight) in the absence of any 
expensive photocatalyst, albeit large amount of reagents were 
required.  
 
Scheme 6. Photochemical perfluoroalkylation of Trp-containing peptides. 
The oxidative decomposition pathway of the sulfinate group, the 
sulfur congener of a carboxylate, was described by Langlois in the 
90s.[7d] However, it took a couple of decades to conceive the so-
named Langlois reagent (CF3SO2Na) as an easy-to-handle, 
inexpensive and versatile trifluoromethyl source. The major 
breakthrough in the field was introduced by Baran and co-workers 
in 2011, who developed a water-compatible and highly practical 
C–H trifluoromethylation of numerous heteroarenes showcasing 
its widespread use in organic synthesis.[39] In that seminal report, 
the innate chemical reactivity of a variety of nitrogen-containing 
heterocycles was leveraged toward the ensuing electrophilic 
radical species derived from the Langlois reagent. Shortly 
thereafter, the same group reported on the improved yields and 
selectivity by using zinc sulfinate analogues,[40] which have 
recently evolved into safe alkyl radical precursors commonly 
employed by the medicinal chemistry community.[41] Inspired by 
these fundamental studies, Davis and Gouverneur reported the 
selective and unprecedented Trp radical trifluoromethylation 
within native proteins.[42] Based on preliminary residue-specific 
selectivity assays involving equimolar mixtures of five native 
amino acid residues (Trp, Phe, Tyr, His and Cys) with the system 
previously employed by Baran (Langlois reagent/TBHP), they 
observed the preferential modification of the Trp residue at pH = 
6. Remarkably, not even the highly nucleophilic thiol motif within 
Cys was affected, thus offering new promising perspectives for 
the challenging site-selective modification of proteins. Accordingly, 
they succeeded in the trifluoromethylation of biomolecules of high 
structural complexity containing one Trp unit, such as melittin (a 
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26-residue peptide) and the protein panthotenate synthetase, two 
Trp units such as hemoprotein myoglobin, or even the enzyme 
lysozyme with up to six Trp residues and a high number of Cys 
units, which remained unaltered. Although apparent adverse 
effects on the proteins were not detected, the required huge 
excess amounts of both Langlois reagent and oxidant (200 and 
up to 25 equivalents, respectively) may raise concerns regarding 
operational safety and could undermine the atom-economy and 
sustainability of the process. Related proteins have been 
trifluoromethylated through laser-initiated processes featuring the 
use of Langlois reagent in combination with inexpensive H2O2.[43] 
Although of high relevance within the field of preoteomics, site-
selectivity was not achieved and the electrophilic CF3 was found 
to react with 18 of the 20 common amino acids. 
 
Scheme 7. Ir-catalyzed trifluoromethylation of Trp-containing peptides. 
Driven by their experience in photoredox catalysis, Lei and co-
workers have recently reported a visible-light induced Ir-catalyzed 
radical C2-trifluoromethylation of a variety of Trp-containing short 
peptides with Langlois reagent.[44] Unlike previous examples,[32-36] 
the method was found applicable for the selective modification of 
a number of di-, tri- and tetrapeptides bearing amino acids with 
unprotected alcohols such as Tyr, Thr and Ser, or the carboxyl 
group such as Asp, among others (Scheme 7). The robustness of 
the protocol was illustrated by the gram-scale trifluoromethylation 
of Ac-Trp-OMe and, importantly, an aqueous solvent system 
could be utilized, albeit higher yields were obtained in neat 
acetonitrile. Control experiments with radical traps along with 
electron paramagnetic resonance (EPR) studies supported a 
radical-radical coupling mechanism. Upon blue LED irradiation, 
the Ir-based photocatalyst could be excited and further assisted 
SET events with both the Trp-containing peptide and Langlois 
reagent to produce a Trp radical cation and CF3 species, 
respectively. Subsequent radical-radical coupling would render 
the corresponding carbocation intermediate, which would 
eventually furnish the trifluoromethylated compound through a 
facile deprotonation step. The authors did not entirely rule out an 
alternate innate radical addition of the transient CF3 species to 
the corresponding electron-rich Trp residue.  
 
Scheme 8. Cu-catalyzed trifluoromethylation of Trp-containing peptides. 
As part of their interest within the radical diversification of 
peptides,[45] Correa and co-workers have recently reported a 
complementary, yet sustainable radical Cu-catalyzed 
trilfuoromethylation of a myriad of Trp-containing oligopeptides 
comprising di-, tri-, tetra- and pentapeptides (Scheme 8).[46] This 
scalable modular coupling was distinguished by its site-specificity, 
functional group tolerance and full chemoselectivity for Trp 
residues over other amino acids and heterocyclic units. In fact, 
the scope could be extended beyond natural peptides and its 
predictable nature was underpinned by the innate reactivity of the 
indole scaffold to undergo preferential C–H trifluoromethylation in 
the presence of other competing sites within medicinally important 
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heterocycles such as pyridines, 1,2,3-triazoles and 
tetrahydrofuran. Notably, Trp derivatives housing functional 
groups such as nitriles as well as biologically relevant cores and 
active pharmaceuticals, including those derived from fatty acids 
(palmitic and oleic acid), ibuprofen and aspirine could be 
accommodated, thereby providing straightforward access to new 
peptide entities of utmost structural complexity. Whereas the 
oftentimes oxidizable Met residue remained intact along the 
process, Cys-containing peptides were found incompatible. 
Remarkably, HPLC and X-ray analysis verified that the reaction 
took place with preservation of the α-center chirality of the starting 
Trp derivatives. The foremost advantage of the method entailed 
the use of inexpensive and safe (NH4)2S2O8 as the oxidant under 
an air atmosphere, thus replacing the commonly used TBHP in 
these endeavors. On the basis of careful control experiments 
which underpinned the key role of the cost-efficient copper 
catalyst to obtain the tagged peptides in higher yields, a plausible 
reaction mechanism was proposed. The Cu(I)-assisted redox 
decomposition of peroxydisulfate ion would initially deliver the 
sulfate radical anion SO4˙ˉ, which upon reaction with CF3SO2ˉ 
would afford the active trifluoromethyl radical species. The latter 
would next undergo innate radical addition at the C2 position of 
the electron-rich indole motif, and subsequent re-oxidation of the 
ensuing radical intermediate would afford the targeted 
trifluoromethylated peptide. 
 
Scheme 9. 18F-trifluoromethylation of Trp-containing native peptides. 
In yet another impressive and elegant display of efficient 
radiolabeling of peptides,[25] Davis and Gouverneur designed a 
one-step synthesis of the radiolabeling trifluoromethyl source 
[18F]CF3SO2NH4 and its application to the late-stage 18F-
trifluoromethylation of a sheer number of Trp-containing native 
peptides of high structural complexity[47] and certain Tyr-
containing biomolecules (vida infra) (Scheme 9). In-depth 
experimental studies led to the optimal synthesis of the 
corresponding 18F reagent, which was eventually performed via 
reaction of 2,2,-difluoro-2-(triphenylphosphonio)acetate (PDFA) 
with N-methylmorpholine·SO2 (NMM·SO2) in the presence of 
[18F]KF/K222 in a mixture of propylene carbonate and DMF as 
solvent at 110 ºC. The resulting radiolabeled trifluoromethyl 
reagent was purified by reversed phase HPLC and obtained with 
99% radiochemical purity. The combination of the latter as the 
limiting reagent with stoichiometric amounts of an iron(III) salt, 
either Fe(NO3)3·9H2O or FeCl3, and TBHP as oxidant was shown 
effective in the site-selective and very fast 18F-trifluoromethylation 
of the Trp unit embedded within a range of oligopeptides, 
including dipeptides bearing Met, Tyr, His, Lys, Phe, Thr and Asp 
residues, among others, in radiochemical conversions up to 56%. 
Importantly, the method boded well for tagging compounds of 
paramount biological relevance such as endomorphin-1 (a 
tetrapeptide associated with Alzheimer’s disease), melittin or the 
cyclopeptide octreotide, among others. It is noteworthy that in all 
cases preferential modification of the Trp residue over other 
amino acids was observed, albeit the corresponding C2-
trifluoromethylated compounds were sometimes accompanied 
with minor amounts of the corresponding C4 and C7-fluorinated 
Trp-regioisomers. As an added bonus of the method, they re-
optimized several reaction parameters to perform a fully 
automated radio-synthesis of octreotide labeled within the 
corresponding Trp unit and further in vivo PET imaging 
experiments. Without any doubt, this ground-breaking discovery 
will set the stage for futures advances within the field of 
radiolabeling of peptides and proteins. In must be emphasized 
that, unlike some of the existing Trp-diversification techniques,[12] 
the set of protocols described along this section occur in NH-free 
Trp-containing compounds and the presence of a directing group 
into the nitrogen atom of the indole core is not required. 
2.4. Trifluoromethylation of Tyrosine (Tyr) 
Tyr constitutes a highly abundant non-essential proteinogenic 
amino acid, which is a prevalent scaffold in a plethora of relevant 
biologically active compounds such as neurotransmitters and 
hormones, as well as a versatile precursor to a variety of alkaloids. 
Accordingly, Tyr-containing derivatives are of widespread use in 
pharmaceutical, dietary supplements or food additives.[48] Its 
chemical reactivity is dictated by the electron-rich phenol-
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containing aromatic side-chain, which can be tuned by pH control. 
While the ortho-C–H bond can be modified through alkylation, 
arylation or Mannich-type reactions in acidic or neutral conditions, 
the modification at the oxygen atom is often achieved under basic 
environments.[12k] Unlike the trifluoromethylation of the Trp unit, 
the parent process featuring Tyr-containing peptides has been 
sparsely explored.  
Early reports by Langlois in 1991 demonstrated the feasibility of 
the radical trifluoromethylation of electron-rich phenol derivatives 
with large excess of the CF3SO2Na/TBHP system and catalytic 
ammounts of Cu(OTf)2.[7d] However, the very first 
trifluoromethylation of a Tyr derivative was achieved upon 
ultraviolet irradiation with CF3I and triethylamine in MeOH 
(Scheme 10).[49] Despite the moderate yield and prolonged 
reaction times, the reaction could be scaled up and performed 
with almost 30 grams of N-trifluoroacetyl-Tyr-OMe as substrate, 
and the process was favored to occur at C2 over C3 in a 95:5 ratio. 
 
Scheme 10. First C2-trifluoromethylation of a Tyr derivative. 
This challenging transformation remained dormant until 2018, 
when Merck laboratories disclosed a highly reliable radical C–H 
trifluoromethylation of a vast collection of unprotected Tyr-
containing peptides of utmost biological significance with 
trifluoromethyl sulfinate salts.[50] Slight modifications of the 
method by Baran featuring the use of Zn(SO2CF3)2 and high 
excess of TBHP in aqueous media led to the selective 
trifluoromethylation of a variety of unprotected Tyr-containing 
dipeptides in 35-48% yields (Scheme 11, method A). Importantly, 
potentially reactive residues such as Lys, Asp, Ser and even 
guanidine-containing Arg, among others, were perfectly 
accommodated and the trifluoromethylation selectively occurred 
at the Tyr unit. Conversely, electron-rich Trp unit was shown more 
reactive, thus being preferentially fluorinated under those 
conditions, and Cys residue was oxidized to its corresponding 
disulfide dimer. In order to increase the utility of the method in 
more intricate settings, careful screening studies allowed the 
replacement of the chemical oxidant by milder photoredox 
catalysis, which enabled the use of a large excess of the Langlois 
reagent for the unprecedented trifluoromethylation of unprotected 
polypeptides of high structural complexity (Scheme 11, method 
B). 
 
Scheme 11. 18F-trifluoromethylation of Tyr-containing native peptides. 
The Ir-based photoredox conditions provided slightly higher yields 
in the site-selective trifluoromethylation of biomolecules of utmost 
significance such as cyclopeptides, deltorphin I, angiotensin I and 
II or β-casomorphin and afforded the mono-trifluoromethylated 
Tyr derivatives as the major product. The most spectacular 
application of this labeling technique was the trifluoromethylation 
of each of the four Tyr residues present in the recombinant human 
insulin, which comprised two peptide chains of 21 and 30 amino 
acid length each, linked by three disulfide bonds. Likewise, 
preliminary studies allowed the installation of other fluoroalkyl 
motifs at the ortho C–H bonds of Tyr units within a cyclopeptide, 
albeit in low yields, thus paving the way to new opportunities in 
tagging biomolecules of great significance. 
As highlighted before, Davis and Gouverneur have recently 
reported the synthesis of a novel, yet efficient, radiolabeled 
trifluoromethylating reagent for the late-stage 18F-
trifluoromethylation of electron-rich Trp and Tyr residues 
embedded into native peptides of great complexity (vide supra).[47] 
As disclosed in Scheme 12, Tyr-containing peptides including His 
or highly sensitive thioether-containing Met unit could be 
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radiolabeled in a late-stage fashion. Importantly, as the method 
by Parish, Krska and co-workers, unprotected peptides with up to 
51 amino acid residues such as recombinant human insulin could 
undergo the challenging 18F- trifluoromethylation process, thereby 
enabling the installation of the radiolabeled trifluoromethyl group 
at the four existing Tyr units. The latter reinforced the potential 
utility of this radiolabeled trifluoromethyl source within the field of 
PET-based molecular imaging.  
 
Scheme 12. 18F-Trifluoromethylation of Tyr-containing native peptides. 
2.5. Trifluoromethylation of Histidine (His) 
Among the collection of natural amino acids, His is a rather 
versatile member that plays multiple roles in protein 
interactions.[51] Given the ionizable nature at physiological 
conditions of the imidazole group and its high binding ability, His 
can behave as a powerful hydrogen bond donor or acceptor within 
a number of enzymatic catalytic reactions in living systems and is 
prevalent in a vast array of metalloproteins.[52] However, the site-
selective modification of such a privileged residue has been 
overlooked in peptide chemistry and chemoselective modification 
of His derivatives remain elusive.[12k] 
 
Scheme 13. Early examples of the trifluoromethylation of His derivatives. 
Early reports on the trifluoromethylation of simple imidazoles 
through photocalysis by Cohen and co-workers[53] lay the 
foundation for the development of further trifluoromethylation 
reactions of His-containing compounds.[54] The use of CF3I in 
MeOH under UV light irradiation led to the radical 
trifluoromethylation of His derivatives at the C4 site of the 
imidazole ring accompanied with significant amounts of the C2 
trifluoromethylated isomers. Despite the moderate site-selectivity 
profile, the protocol showed a remarkable ease for scale-up, and 
more than 20 grams of N-CF3CO-His-OMe underwent the 
corresponding photochemical trifluoromethylation to provide a 
separable mixture of C4 and C2 regioisomers in 59% overall yield. 
Driven by the last trends in radical chemistry and with the aim to 
expand the tagging toolkit of peptides, Noisier, Gopalakrishnan 
and co-workers have recently disclosed a bio-compatible and 
late-stage efficient alkylation platform with exquisite selectivity 
toward the C2-alkylation of an impressive His-containing 
compound library.[55] The key feature relied on the use of the 
sulfinate salts developed by Baran as powerful radical precursors 
under oxidative conditions.[41] Although a huge excess of both 
sulfinate and oxidant was required, the reaction could be 
performed in a convenient aqueous environment, which rendered 
the method applicable in a vast array of highly complex bioactive 
peptides, some of them selected from the AstraZeneca drug-
candidate collection. Whereas the trifluoromethylation reaction 
occurring at the C2-site of the imidazole ring in the presence of 
either Langlois reagent or its zinc sulfinate analogue was 
achieved in low yields, an extensive set of fluorinated motifs could 
be efficiently installed at the C2-site of His residue in a late-stage 
fashion (Scheme 14). Noteworthy, when using oligopeptides 
housing more nucleophilic Trp and Tyr residues, the use of the 
Langlois reagent favored the preferential trifluoromethylation of 
the latter residues, thus leaving His residue unreactive. 
Conversely, by switching to MeCF2SO2Na, the corresponding 
difluoroethylation took place selectively at the His unit. Likewise, 
the reactivity pattern wherein aromatic His residue was selectively 
modified in the presence of Trp and Tyr residues was also 
observed when utilizing non-fluorinated alkyl radical 
precursors.[56] Although the mechanism of these 
trifluoromethylation reactions are not commented in the original 
publications, a plausible scenario would likely entail a Minisci-type 
C–H functionalization step of the imidazole core with the ensuing 
electrophilic radical species.[57] 




Scheme 14. Fluoroalkylation of His-containing unprotected peptides. 
3. Conclusions and Outlook 
The development of useful synthetic tools to label canonical 
amino acids within a peptide framework for the ultimate 
modification of proteins in a late-stage, yet site-selective fashion 
has recently received increasing attention within the realm of 
chemical biology. In particular, the incorporation of a 
trifluoromethyl group represents a challenging goal of capital 
importance due to the improved metabolic stability, bioavailability 
and cellular membrane permeability of the resulting 
trifloromethylated compounds. With the advent of modern C–H 
functionalization, the last decade has witnessed the upsurge of a 
set of powerful trifluoromethylation techniques, hence enabling 
the rapid assembly of a new library of trifluoromethylated peptides 
and proteins in a sustainable manner. The latter commonly 
harness the inherent reactivity of the side-chains of certain amino 
acid residues, such as nucleophilic Cys, Tyr, Trp and His, for 
generating new peptide and protein analogues housing 
metabolism blocking fluoroalkyl groups. This review details the 
currently available toolbox of trifluoromethylation reactions, 
classified by their site-selectivity pattern with proven applicability 
to oligopeptides of great structural complexity and medicinal 
relevance. Despite the advances realized, several challenges 
need to be addressed in order to improve the practicality of the 
existing protocols and design other innovative strategies. In 
principle, an ideal protein bioconjugation manifold should be site-
selective and proceed under mild reaction conditions, while 
preserving the native protein structure. Accordingly, the peptide 
chemistry landscape clearly demands toward bioorthogonal 
reactivity and compatibility with the 20 natural existing set of 
unprotected amino acids under physiological reaction conditions 
and with full tolerance to aqueous environments.  
Emerging trends in this rapidly evolving interdisciplinary field are 
expected to solve the former and the following issues. First, the 
existing trifluoromethylation reactions are currently limited to a low 
number of natural amino acids and hence the installation of the 
trifluoromethyl group into other residues still represents an unmet 
challenge. Second, some of the reported protocols are not yet 
broadly applicable to complex peptides and relied on the use of 
fully protected short-peptide sequences. Third, huge amount of 
both trifluoromethylating agents or chemical oxidants as well as 
Ir-based photoredox catalysts are often required, thus diminishing 
the atom-economy, sustainability and practicality of the protocol. 
In this respect, the use of electricity remains an unexplored 
avenue in these endeavors; an electrochemical setup could avoid 
the use of chemical oxidants and the generation of byproducts 
derived thereof as well as the use of often expensive photoredox 
catalysts. Likewise, as commented above, flow-chemistry has 
already demonstrated its beneficial effects by shortening reaction 
times and improving the reaction efficiency, therefore it stands out 
as another challenging technology to be implemented in future 
late-stage peptide diversifications. Finally, the downstream 18F-
radiolabeling of peptides still remains in its infancy and the cutting-
edge methods developed by Davis and Gouverneur would clearly 
set the stage for future discoveries of paramount significance in 
biomedicinal chemistry. In summary, we anticipate that efforts 
along these lines could have a significant impact on this field of 
expertise, which has not reached yet its full synthetic potential and 
we hope this review could serve as a practical user guide, while 
encouraging practitioners in the field to search for innovative 
trifluoromethylation reactions within fascinating peptide settings in 
the years to come. 
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